Skip to content
lifestyle.utv.ie
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Aardvark Therapeutics, Inc.
Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials
October 23, 2026
Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE Data
October 22, 2026
Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors
October 8, 2026
Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 2, 2026
Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 11, 2026
Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold
May 14, 2026
Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
May 7, 2026
Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive Officer
February 12, 2026
Aardvark Therapeutics Announces Leadership Appointments
February 12, 2026
Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101, Expanding Eligibility in Phase 3 Study of Prader-Willi Syndrome
February 11, 2026